A Luminescent Biosensor for Ex Vivo Detection of Her2-Positive Breast Cancer Based on a Novel Affiprobe

A Luminescent Biosensor for Ex Vivo Detection of Her2-Positive Breast Cancer Based on a Novel Affiprobe Publisher

Nazari M¹ ; Emamzadeh R² ; Minaitehrani A³ ; Nasir Shirazi M¹ ; Naimi A⁴

Show Affiliations

1. Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
2. Department of Biology, Faculty of Sciences, University of Isfahan, Isfahan, Iran
3. Nanobiotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
4. Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Analytical Methods Published:2019

Abstract

A novel receptor tyrosine-protein kinase erbB-2 (HER2)-binding affiprobe-named ZHER2:342-RLuc-was designed, produced and assessed in terms of function to detect HER2 positive cells and for preliminary clinical diagnosis. The ZHER2:342 affibody with affinity for HER2 was fused to Renilla luciferase, and the purified affiprobe was used for detection of HER2 positive cells as well as evaluation of surgical specimens from breast cancer patients. The results showed that the affiprobe can specifically bind to HER2 positive cells, and therefore, it may be used for molecular detection. © 2019 The Royal Society of Chemistry.

Related Docs

1. New Insights Into Affinity Proteins for Her2-Targeted Therapy: Beyond Trastuzumab, Biochimica et Biophysica Acta - Reviews on Cancer (2020)

2. Mir-195 Down-Regulation Is a Distinctive Biomarker of Her2 Positive State in Breast Cancer, Gene Reports (2020)

3. Ephb4 Tyrosine Kinase Stimulation Inhibits Growth of Mda-Mb-231 Breast Cancer Cells in a Dose and Time Dependent Manner, Disease Markers (2013)

4. Evaluation of Immunohistochemistry Technique in Detecting Her2 Overexpression in Invasive Ductal Breast Carcinoma Using Fluorescence In-Situ Hybridization Method, Journal of Isfahan Medical School (2016)

5. Production and Characterization of New Anti-Her2 Monoclonal Antibodies, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy (2015)

Experts (# of related papers)

View all Related Experts

Vajihe Akbari (1)

Hamid Mirmohammad Sadeghi (1)

Style	Citing Format
MLA	Nazari M, et al.. "A Luminescent Biosensor for Ex Vivo Detection of Her2-Positive Breast Cancer Based on a Novel Affiprobe." Analytical Methods, vol. 11, no. 33, 2019, pp. 4233-4241.
APA	Nazari M, Emamzadeh R, Minaitehrani A, Nasir Shirazi M, Naimi A (2019). A Luminescent Biosensor for Ex Vivo Detection of Her2-Positive Breast Cancer Based on a Novel Affiprobe. Analytical Methods, 11(33), 4233-4241.
Chicago	Nazari M, Emamzadeh R, Minaitehrani A, Nasir Shirazi M, Naimi A. "A Luminescent Biosensor for Ex Vivo Detection of Her2-Positive Breast Cancer Based on a Novel Affiprobe." Analytical Methods 11, no. 33 (2019): 4233-4241.
Harvard	Nazari M et al. (2019) 'A Luminescent Biosensor for Ex Vivo Detection of Her2-Positive Breast Cancer Based on a Novel Affiprobe', Analytical Methods, 11(33), pp. 4233-4241.
Vancouver	Nazari M, Emamzadeh R, Minaitehrani A, Nasir Shirazi M, Naimi A. A Luminescent Biosensor for Ex Vivo Detection of Her2-Positive Breast Cancer Based on a Novel Affiprobe. Analytical Methods. 2019;11(33):4233-4241.
BibTex	@article{ author = {Nazari M and Emamzadeh R and Minaitehrani A and Nasir Shirazi M and Naimi A}, title = {A Luminescent Biosensor for Ex Vivo Detection of Her2-Positive Breast Cancer Based on a Novel Affiprobe}, journal = {Analytical Methods}, volume = {11}, number = {33}, pages = {4233-4241}, year = {2019} }
RIS	TY - JOUR AU - Nazari M AU - Emamzadeh R AU - Minaitehrani A AU - Nasir Shirazi M AU - Naimi A TI - A Luminescent Biosensor for Ex Vivo Detection of Her2-Positive Breast Cancer Based on a Novel Affiprobe JO - Analytical Methods VL - 11 IS - 33 SP - 4233 EP - 4241 PY - 2019 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract